A one-time dose of BEQVEZ has reduced bleeds post-treatment compared to standard of care with a median of zero bleeds after up to three years of follow-up, providing sustained bleed protection and.
ATTRibute-CM results also demonstrated rapid clinical benefit on the composite endpoint of all-cause mortality (ACM) and CVH in patients treated with acoramidis, with time-to-first event Kaplan-Meier curves separating at month 3 and continuing to diverge steadily through Month 30
Vera Therapeutics, Inc. announced the appointments of two industry veterans to help lead the development of the company?s drug programs including its late-stage product candidate, atacicept, to treat.
Gene Therapy Briefs: Activist Investor Reported to Take $1B Stake in BioMarin genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.